BioNTech announced an all-stock acquisition of German mRNA vaccine peer CureVac for approximately $1.25 billion. The deal, positioned as a resolution to ongoing patent litigation between the companies, enhances BioNTech's oncology and mRNA technology capabilities. CureVac shareholders will hold around 4-6% of BioNTech post-close. The acquisition is expected to close later this year.